Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Maissaa Janbain, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Radu Bolbos, Cindy A. Leissinger, MD, Yesim Dargaud, MD PhD

Blood (2018) 132 (Supplement 1): 2490.

https://doi.org/10.1182/blood-2018-99-119407

Published: 2018

Journal Articles

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Sandra Le Quellec, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Vladmir Jacqueline, Claude Negrier, MD, Yesim Dargaud, MD PhD

Blood (2017) 130 (Supplement 1): 2339.

https://doi.org/10.1182/blood.V130.Suppl_1.2339.2339

Published: 2017

Journal Articles

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Yesim Dargaud, MD PhD, Anne Lienhart, MD, Nathalie Enjolras, PhD, Claude Negrier, MD

Blood (2017) 130 (Supplement 1): 3675.

https://doi.org/10.1182/blood.V130.Suppl_1.3675.3675

Published: 2017

Journal Articles

Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice

Sandra Le Quellec, MD, Allison P Dane, PhD, Claude Negrier, Yesim Dargaud, MD PhD, Amit C Nathwani, MD PhD, Nathalie Enjolras, PhD

Blood (2017) 130 (Supplement 1): 4610.

https://doi.org/10.1182/blood.V130.Suppl_1.4610.4610

Published: 2017

Journal Articles

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Nathalie Enjolras, PhD, Yesim Dargaud, MD, PhD, Jean-Luc Plantier, PhD, Heli Simpson, Florine Guillaume, Claude Negrier, MD

Blood (2009) 114 (22): 4202.

https://doi.org/10.1182/blood.V114.22.4202.4202

Published: 2009

Journal Articles

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Veronique Rolli, Ph D, Nathalie Enjolras, PhD, Cecile Ducasse, Marie-Helene Rodriguez, PhD, Thomas Weimer, PhD, Hans-Peter Hauser, PhD, Claude Negrier, MD, PhD, Jean-Luc Plantier, Ph D

Blood (2004) 104 (11): 1729.

https://doi.org/10.1182/blood.V104.11.1729.1729

Published: 2004

NARROW

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Email alerts

ASH Publications

American Society of Hematology

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only